Article Text

Download PDFPDF
Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.



Is paliperidone (risperidone’s active metabolite) an effective treatment for schizophrenia?


Several outcomes were assessed by the review including death (suicide and natural causes), mental state, cognitive and social functioning, behaviour, quality of life and adverse effects.



Systematic review with meta-analysis.

Data sources:

Cochrane Schizophrenia Group’s Register was searched up to December 2006.

Study selection and analysis:

RCTs examining effects of any dose of adjunct paliperidone (oral or intramuscular) in people with schizophrenia or schizophrenia-like illness (using any diagnostic criteria), regardless of age or sex. Studies were rated to determine risk of bias; those rated as at high risk of bias were not included in the review. Studies with more than 50% dropout were excluded as were studies using rating scales that had not been described in a peer-reviewed journal. A conservative intention-to-treat analysis was used, where dropouts were assumed to have had the negative outcome (except death). Risk ratios and NNTs were calculated for binary outcomes. Weighted mean differences were calculated for continuous measures …

View Full Text


  • Source of funding: Department of Psychiatry, University of North Carolina Hospitals, USA.


  • Competing interests: None.